1. Verify oral stability
Confirm the immediate-release oral haloperidol dose, duration, adherence, response, side effects, and reason for considering a long-acting injection.
The current label describes adult schizophrenia after stabilization on immediate-release oral haloperidol. The decanoate is a long-acting, deep intramuscular injection, usually every four weeks. It must not be given into a vein and is different from short-acting haloperidol injections. The prescriber calculates an individual start and maintenance plan and reviews cardiac, movement and interaction risks. There is no single fixed oral-overlap duration for every patient. Continuing care includes symptom review, movement assessment and appropriate ECG and electrolyte monitoring.
Haloperidol decanoate is a long-acting antipsychotic injection for adults with schizophrenia who were previously stabilized on immediate-release oral haloperidol. A healthcare professional gives it as a deep intramuscular injection, usually every four weeks. The decanoate formulation must not be given into a vein. It differs from short-acting haloperidol injections used in other settings.
Haloperidol blocks dopamine receptors. The decanoate formulation releases haloperidol gradually from the injection site. This can reduce the need for daily administration, but it also means an adverse effect may continue after the next injection is withheld. The formulation does not remove the need for psychiatric review, movement assessment or physical-health monitoring.
The prescriber reviews the stable oral haloperidol regimen, previous response and side effects before calculating the injection plan. Tell the clinician about fainting, heart rhythm problems, low potassium or magnesium, seizures, Parkinson’s disease, Lewy body dementia and every other medicine. These details can change whether haloperidol is appropriate or which monitoring is needed.
Bring the oral dose, duration, response and prior adverse effects. The prescriber chooses the starting regimen. The label limits the first injection to 100 mg. A larger calculated initial amount requires a prescribed staged sequence rather than one larger first injection.
An ECG and electrolytes are checked at baseline and during treatment as clinically indicated. Explain any muscle stiffness, tremor, severe restlessness, falls or involuntary movements. The team also reviews other medicines that affect heart rhythm or haloperidol levels.
Record the product, dose and actual injection date. If symptoms worsen while the dose is being adjusted, the prescriber may consider supplemental immediate-release oral haloperidol. This is an individual decision, not permission to add leftover tablets.
Bring the exact product name, prescribed strength, last injection date, oral medicine list and the responsible prescriber’s contact information. Include discharge notes, recent blood tests and any written start or restart plan. Tell the team about pregnancy, breastfeeding, allergies, seizures, fainting, substance use and new medicines or supplements. If a dose is delayed or records are unclear, contact the prescriber before travelling to an administration visit. Tell the team if you take lithium or another medicine associated with heart-rhythm effects. Ask about the planned ECG, blood tests and movement assessment before administration.
The boxed warning states that antipsychotics increase the risk of death in older adults with dementia-related psychosis. This medicine is not approved for that use. Haloperidol can cause serious heart-rhythm problems, movement disorders, sedation, dizziness and falls. Stiffness or restlessness should be reported promptly. Severe fever, rigid muscles and confusion may signal neuroleptic malignant syndrome and require emergency care. Parkinson’s disease and Lewy body dementia are contraindications. Avoid driving or hazardous tasks until you know whether treatment impairs alertness. Seek emergency care for severe trouble breathing, throat or tongue swelling, loss of consciousness, or high fever with severe muscle stiffness and confusion. Contact the treating team promptly for new involuntary movements, severe restlessness, worsening psychosis, marked dizziness or troublesome injection-site symptoms. Do not wait for the next routine injection to report a serious concern.
A missed appointment requires the responsible prescriber to review the actual last injection date, symptoms and any oral treatment. The label does not supply one universal missed-dose formula for all situations. Keep scheduled psychiatric and physical-health reviews even when injections are being administered regularly. Tell the team before changing lithium, alcohol use or sedating medicines.
Before an injection appointment, ask which clinic can accept the prescription, how the medicine will be obtained, and which costs belong to the medicine, administration and psychiatry follow-up. A benefits check, prior authorization and medicine delivery are different steps. Ask for the proposed cost before each step. Manufacturer assistance has its own eligibility rules. Office-visit coverage does not establish medication coverage, and a listed clinic does not establish that the product is stocked or can be given there today.
Haloperidol decanoate is a long-acting antipsychotic injection for adults with schizophrenia who were previously stabilized on immediate-release oral haloperidol. A healthcare professional gives it as a deep intramuscular injection, usually every four weeks. The decanoate formulation must not be given into a vein. It differs from short-acting haloperidol injections used in other settings.
The prescriber reviews the stable oral haloperidol regimen, previous response and side effects before calculating the injection plan. Tell the clinician about fainting, heart rhythm problems, low potassium or magnesium, seizures, Parkinson’s disease, Lewy body dementia and every other medicine. These details can change whether haloperidol is appropriate or which monitoring is needed.
Bring the oral dose, duration, response and prior adverse effects. The prescriber chooses the starting regimen. The label limits the first injection to 100 mg. A larger calculated initial amount requires a prescribed staged sequence rather than one larger first injection.
An ECG and electrolytes are checked at baseline and during treatment as clinically indicated. Explain any muscle stiffness, tremor, severe restlessness, falls or involuntary movements. The team also reviews other medicines that affect heart rhythm or haloperidol levels.
Record the product, dose and actual injection date. If symptoms worsen while the dose is being adjusted, the prescriber may consider supplemental immediate-release oral haloperidol. This is an individual decision, not permission to add leftover tablets.
An online request is not enough to establish a safe conversion dose. The responsible prescriber reviews the exact product, current oral/injection dose, tolerability, prior doses, medical conditions, interactions and label instructions before issuing an order. The administration service must receive the documented regimen and restart plan. Do not use an online calculator or another person’s order to convert treatment.
A missed appointment requires the responsible prescriber to review the actual last injection date, symptoms and any oral treatment. The label does not supply one universal missed-dose formula for all situations. Keep scheduled psychiatric and physical-health reviews even when injections are being administered regularly. Tell the team before changing lithium, alcohol use or sedating medicines.
The prescriber reviews the stable oral haloperidol regimen, previous response and side effects before calculating the injection plan. Tell the clinician about fainting, heart rhythm problems, low potassium or magnesium, seizures, Parkinson’s disease, Lewy body dementia and every other medicine. These details can change whether haloperidol is appropriate or which monitoring is needed.
The boxed warning states that antipsychotics increase the risk of death in older adults with dementia-related psychosis. This medicine is not approved for that use. Haloperidol can cause serious heart-rhythm problems, movement disorders, sedation, dizziness and falls. Stiffness or restlessness should be reported promptly. Severe fever, rigid muscles and confusion may signal neuroleptic malignant syndrome and require emergency care. Parkinson’s disease and Lewy body dementia are contraindications. Avoid driving or hazardous tasks until you know whether treatment impairs alertness. Seek emergency care for severe trouble breathing, throat or tongue swelling, loss of consciousness, or high fever with severe muscle stiffness and confusion. Contact the treating team promptly for new involuntary movements, severe restlessness, worsening psychosis, marked dizziness or troublesome injection-site symptoms. Do not wait for the next routine injection to report a serious concern.
A missed appointment requires the responsible prescriber to review the actual last injection date, symptoms and any oral treatment. The label does not supply one universal missed-dose formula for all situations. Keep scheduled psychiatric and physical-health reviews even when injections are being administered regularly. Tell the team before changing lithium, alcohol use or sedating medicines.
Nao Medical can coordinate psychiatric injection care with your prescribing psychiatrist. Share the current order, exact medicine, last dose date and treatment history through the confirmed clinical intake process. The clinicians review product-specific initiation or restart requirements and arrange medication delivery, administration and follow-up. Keep your existing treatment plan until the next appointment is agreed.
Contact the treating team promptly. Movement symptoms need assessment and a treatment review. Severe fever with rigidity and confusion requires emergency care.
Haloperidol decanoate is an oil-based injection intended for deep intramuscular administration by a healthcare professional. It is not a subcutaneous injection and must not be given into a vein. The label does not establish a specific mechanism explaining irritation from an incorrect under-the-skin injection. Contact the treating team if you think the wrong route was used or have persistent pain, redness or swelling. They can assess the site and treatment record.
Confirm the immediate-release oral haloperidol dose, duration, adherence, response, side effects, and reason for considering a long-acting injection.
Assess movement symptoms, prior neuroleptic malignant syndrome, QT or rhythm risk, Parkinson's disease or Lewy body dementia, seizures, pregnancy, and interacting medicines.
Review the signed dose and date, outside-prescriber responsibility, benefits, acquisition path, patient-specific medication, and arrival at the eligible site.
Document deep intramuscular administration, monitor immediate concerns, continue psychiatric follow-up, and plan the next four-week dose.
Bronx
932 E 174th St, Bronx, NY 10460
If an outside psychiatrist manages treatment, send the order and records for Nao review. If not, Nao psychiatry can evaluate and manage the plan. Medication delivery, trained staff, and the administration site must be confirmed before travel.
Queens
37-15 23rd Ave, Astoria, NY 11105
If an outside psychiatrist manages treatment, send the order and records for Nao review. If not, Nao psychiatry can evaluate and manage the plan. Medication delivery, trained staff, and the administration site must be confirmed before travel.
Bronx
2063A Bartow Ave, Bronx, NY 10475
If an outside psychiatrist manages treatment, send the order and records for Nao review. If not, Nao psychiatry can evaluate and manage the plan. Medication delivery, trained staff, and the administration site must be confirmed before travel.
Brooklyn
341 Eastern Pkwy, Brooklyn, NY 11216
If an outside psychiatrist manages treatment, send the order and records for Nao review. If not, Nao psychiatry can evaluate and manage the plan. Medication delivery, trained staff, and the administration site must be confirmed before travel.
Long Island
232 W Old Country Rd, Hicksville, NY 11801
If an outside psychiatrist manages treatment, send the order and records for Nao review. If not, Nao psychiatry can evaluate and manage the plan. Medication delivery, trained staff, and the administration site must be confirmed before travel.
Queens
80-10 Northern Blvd, Jackson Heights, NY 11372
If an outside psychiatrist manages treatment, send the order and records for Nao review. If not, Nao psychiatry can evaluate and manage the plan. Medication delivery, trained staff, and the administration site must be confirmed before travel.
Queens
90-18 Sutphin Blvd, Jamaica, NY 11435
If an outside psychiatrist manages treatment, send the order and records for Nao review. If not, Nao psychiatry can evaluate and manage the plan. Medication delivery, trained staff, and the administration site must be confirmed before travel.
Queens
30-07 36th Ave, Astoria, NY 11106
If an outside psychiatrist manages treatment, send the order and records for Nao review. If not, Nao psychiatry can evaluate and manage the plan. Medication delivery, trained staff, and the administration site must be confirmed before travel.
Long Island
135 Mineola Blvd, Mineola, NY 11501
If an outside psychiatrist manages treatment, send the order and records for Nao review. If not, Nao psychiatry can evaluate and manage the plan. Medication delivery, trained staff, and the administration site must be confirmed before travel.
Manhattan
259 1st Ave, New York, NY 10003
If an outside psychiatrist manages treatment, send the order and records for Nao review. If not, Nao psychiatry can evaluate and manage the plan. Medication delivery, trained staff, and the administration site must be confirmed before travel.
Brooklyn
308 Graham Ave, Brooklyn, NY 11211
If an outside psychiatrist manages treatment, send the order and records for Nao review. If not, Nao psychiatry can evaluate and manage the plan. Medication delivery, trained staff, and the administration site must be confirmed before travel.
Review the shared outside-order and patient-specific delivery process.
Review another older depot antipsychotic without assuming equivalent conversion or monitoring.
Connect depot treatment with diagnosis, symptoms, movement monitoring, and support needs.
Review interactions, side effects, adherence, and prescriber-led changes.
NIH DailyMed / FDA-approved labeling
Adult schizophrenia indication, stable oral treatment, four-week dosing, interactions, and safety.
Open official sourceAmerican Psychiatric Association
Assessment, antipsychotic treatment, long-acting medicines, clozapine, and monitoring.
Open official sourceU.S. Food and Drug Administration
How patients and clinicians can report suspected medication problems.
Open official sourceContent was updated August 4, 2026 using the sources cited above. Medical guidance, prescribing information, medication availability, and insurance rules can change. A licensed clinician must confirm current information and determine each patient's eligibility, testing, treatment, administration setting, and follow-up. Call 911 for a medical emergency. Contact Nao Medical with a question or correction.